NANOV.OL WACC - Weighted Average Cost of Capital
The WACC of Nordic Nanovector ASA (NANOV.OL) is 9.7%.
| Range | Selected | |
| Cost of equity | 8.5% - 10.9% | 9.7% |
| Tax rate | 0.3% - 0.3% | 0.3% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 8.5% - 10.9% | 9.7% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 5.5% | 6.5% |
| Adjusted beta | 0.83 | 0.92 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.5% | 10.9% |
| Tax rate | 0.3% | 0.3% |
| Debt/Equity ratio | 0 | 0 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 8.5% | 10.9% |
| Selected WACC | 9.7% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| NANOV.OL | Nordic Nanovector ASA | 0 | 2.21 | 2.21 |
| ABVX.PA | Abivax SA | 0.3 | 1.69 | 1.3 |
| BGBIO.OL | Bergenbio ASA | 0.01 | 2.15 | 2.13 |
| HPHA.DE | Heidelberg Pharma AG | 0.14 | 0.36 | 0.32 |
| IVACC.ST | Intervacc AB | 0 | 1.4 | 1.4 |
| MAB.WA | Mabion SA | 0.22 | 0.92 | 0.75 |
| ORY.MC | Oryzon Genomics SA | 0.05 | 0.63 | 0.6 |
| SCLP.L | Scancell Holdings PLC | 0.19 | -0.31 | -0.26 |
| TILS.L | Tiziana Life Sciences PLC | 0.01 | -1.34 | -1.34 |
| VACC.OL | Vaccibody AS | 0 | 1.08 | 1.08 |
| VVY.AS | Vivoryon Therapeutics NV | 0 | 1.2 | 1.2 |
| Low | High | |
| Unlevered beta | 0.75 | 1.2 |
| Relevered beta | 0.75 | 0.88 |
| Adjusted relevered beta | 0.83 | 0.92 |
NANOV.OL's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for NANOV.OL:
cost_of_equity (9.70%) = risk_free_rate (4.15%) + equity_risk_premium (6.00%) * adjusted_beta (0.83) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.